Search research articles
Contact Us
Filters
Showing results (341-350 of 347) with videos related to
Page
of 35
Sort By:
You have reached the last page of results.
This site can display upto 347 results.
The New England Journal of Medicine
|
August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function Genotypes
Peter J Barry, Marcus A Mall, Antonio Álvarez, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Edith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal
|
November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension study
Cori L Daines, Elizabeth Tullis, Stefano Costa, et al.
American Journal of Medical Genetics. Part A
|
February 1, 2017
A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus
P Dunn, G P Prigatano, S Szelinger, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
Marcus A Mall, Rossa Brugha, Silvia Gartner, et al.
Microbiome
|
April 3, 2020
Lung function and microbiota diversity in cystic fibrosis
Leah Cuthbertson, Alan W Walker, Anna E Oliver, et al.
International Journal of Molecular Sciences
|
July 24, 2021
The Critical Importance of Molecular Biomarkers and Imaging in the Study of Electrohypersensitivity. A Scientific Consensus International Report
Dominique Belpomme, George L Carlo, Philippe Irigaray, et al.
Page
of 35
Search research articles
Search
Showing results (341-350 of 347) with videos related to
Sort By:
Page
of 35
You have reached the last page of results.
This site can display upto 347 results.
The New England Journal of Medicine
|
August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function Genotypes
Peter J Barry, Marcus A Mall, Antonio Álvarez, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Edith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal
|
November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension study
Cori L Daines, Elizabeth Tullis, Stefano Costa, et al.
American Journal of Medical Genetics. Part A
|
February 1, 2017
A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus
P Dunn, G P Prigatano, S Szelinger, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
Marcus A Mall, Rossa Brugha, Silvia Gartner, et al.
Microbiome
|
April 3, 2020
Lung function and microbiota diversity in cystic fibrosis
Leah Cuthbertson, Alan W Walker, Anna E Oliver, et al.
International Journal of Molecular Sciences
|
July 24, 2021
The Critical Importance of Molecular Biomarkers and Imaging in the Study of Electrohypersensitivity. A Scientific Consensus International Report
Dominique Belpomme, George L Carlo, Philippe Irigaray, et al.
Page
of 35